CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $31,073 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $681 | $710 | $688 | $632 |
| Gross Profit | $30,392 | -$710 | -$688 | -$632 |
| % Margin | 97.8% | – | – | – |
| R&D Expenses | $80,118 | $67,995 | $64,542 | $35,882 |
| G&A Expenses | $51,953 | $25,116 | $23,040 | $17,425 |
| SG&A Expenses | $51,953 | $25,116 | $23,040 | $17,425 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $132,071 | $93,111 | $87,582 | $53,307 |
| Operating Income | -$101,679 | -$93,111 | -$87,582 | -$52,602 |
| % Margin | -327.2% | – | – | – |
| Other Income/Exp. Net | -$3,691 | -$12,890 | -$2,416 | $1,616 |
| Pre-Tax Income | -$105,370 | -$106,001 | -$89,998 | -$50,986 |
| Tax Expense | $0 | $12,890 | $2,583 | -$2,321 |
| Net Income | -$105,370 | -$118,891 | -$92,581 | -$48,665 |
| % Margin | -339.1% | – | – | – |
| EPS | -0.99 | -1.35 | -1.3 | -0.71 |
| % Growth | 26.7% | -3.8% | -83.1% | – |
| EPS Diluted | -0.99 | -1.35 | -1.3 | -0.71 |
| Weighted Avg Shares Out | 106,204 | 87,804 | 71,055 | 68,893 |
| Weighted Avg Shares Out Dil | 106,204 | 87,804 | 71,055 | 68,893 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,490 | $2,017 | $167 | $1,616 |
| Interest Expense | $18,945 | $14,907 | $2,583 | $0 |
| Depreciation & Amortization | $681 | $2,017 | $855 | -$778 |
| EBITDA | -$85,744 | -$92,401 | -$86,727 | -$50,354 |
| % Margin | -275.9% | – | – | – |